Device meets latest MHRA recommendations and UK Resuscitation Council guidelines
Emerade is now available in the UK
A recent review of adrenaline auto-injectors by the Medicines and Healthcare products Regulatory Agency (MHRA) included new recommendations on performance and dosage.
In the wake of this, iMed Systems announces the launch of Emerade - the first 'pen' to follow both the latest MHRA recommendations and the UK Resuscitation Council's guidelines for healthcare providers.
More than 200,000 men, women and children in the UK live with the risk of suffering a fatal allergic reaction if exposed to a particular trigger. It may be certain foods such as peanuts, or it could be a wasp sting. The condition is known as anaphylaxis. For those at risk, avoiding these triggers can often become a dominant factor in managing their day-to-day life. Unfortunately, avoidance is not always possible and accidental exposure can happen. In these cases the first-line emergency treatment is a rapid injection of adrenaline directly into the thigh muscle.
To maximise the likelihood of achieving the necessary depth of intra-muscular injection, the new Emerade design features longer intra-muscular needles.
Dr Richard Pumphrey, the UK's leading specialist in the field of anaphylaxis fatalities, said: "We have been asking manufacturers to supply auto injectors that have a larger dose and longer needles. We need to get the right dose to the right place. In fact, this is exactly what the UK Resuscitation Council has been recommending for years."
Emerade is now available on NHS prescription across the UK.